Wedbush Maintains Outperform on Dianthus Therapeutics, Lowers Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains an Outperform rating on Dianthus Therapeutics (NASDAQ:DNTH) but lowers the price target from $38 to $36.
August 09, 2024 | 1:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst Laura Chico maintains an Outperform rating on Dianthus Therapeutics but lowers the price target from $38 to $36.
The Outperform rating suggests continued confidence in the stock's performance, but the lowered price target indicates a slight reduction in expected upside. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100